While Eli Lilly continues to ride an historic stretch of company growth and performance in the annals of Big Pharma, the now ...

Parabilis Medicines surged 58% on its first trading day, pushing its market cap to roughly $3.7 billion and cementing its $670 million raise as the largest biotech IPO on record. Parabilis Medicines ...

In today's Pharmaceutical Executive Daily, Parabilis Medicines prices a record-breaking $670 million IPO, Swedish biotech ...

In today's Pharmaceutical Executive Daily, a pharma funding roundup covers two RNA-focused biotechs that secured fresh ...

We have entered a new era, with artificial intelligence (AI) driving one of the fastest technological transformations in ...

Bexobrutideg leverages targeted protein degradation to eliminate BTK, potentially overcoming resistance mutations and ...

The ACCESS Model’s significance for the industry is that it introduces a new level of operational capacity to what remains ...

Most terminated trials stop for enrollment and funding failures, not negative efficacy or safety, making data-collection cost ...

Transaction terms include a $124/share all-cash tender offer, implying a 40% premium to prior close, with expected Q3 2026 closing pending antitrust and customary conditions. Regulatory timelines ...

RNA exon editing enables replacement of multiple entire exons at kilobase scale, potentially addressing large genes and high ...

Under the terms of the agreement, Alnylam will provide $30 million in upfront consideration, including cash and an equity ...

FDA’s draft guidance allows sponsors to leverage public and platform knowledge for CMC, nonclinical, and clinical support of ...